MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer

Table 5

Incidence of excision repair genotypes in head and neck cancer patients. Peripheral blood (PB) and tumor tissue (TT) data.

	ERCC1 C8092A/
	CD3EAP Q504K			ERCC2-312 Asn/Asp				ERCC2-751 Lys/Gln				XRCC1-399 Gln/Arg
	(CAG/AAG)			(AAC/GAC)				(AAG/CAG)				(CAG/CGG)
PB (𝑛=26)	C/C	12	(46.2%)	(G/G)	Asp/Asp	8	(30.8%)	(C/C)	Gln/Gln	4	(15.4%)	(G/G)	Arg/Arg	8	(30.8%)
	A/C	13	(50%)	(A/G)	Asn/Asp	13	(50%)	(A/C)	Lys/Gln	15	(57.7%)	(A/G)	Gln/Arg	15	(57.7%)
	A/A	1	(3.8%)	(A/A)	Asn/Asn	5	(19.2%)	(A/A)	Lys/Lys	7	(26.9%)	(A/A)	Gln/Gln	3	(11.5%)
TT (𝑛=33)	C/C	17	(51.5%)	(G/G)	Asp/Asp	12	(38.7%)	(C/C)	Gln/Gln	5	(16.1%)	(G/G)	Arg/Arg	12	(38.7%)
	A/C	12	(36.4%)	(A/G)	Asn/Asp	15	(48.4%)	(A/C)	Lys/Gln	16	(51.6%)	(A/G)	Gln/Arg	16	(51.6%)
	A/A	4	(12.1%)	(A/A)	Asn/Asn	4	(12.9%)	(A/A)	Lys/Lys	10	(32.3%)	(A/A)	Gln/Gln	3	(9.7%)
	Undet.	0				2				2				2

Undet. = undetermined with real time PCR.